Logo

Rosetta to Collaborate with Unnamed Pharma on microRNA-based Alzheimer's Dx

Jul 31, 2014
Premium

NEW YORK (GenomeWeb) – Rosetta Genomics this week announced that it has signed a deal with an undisclosed global pharmaceutical firm to develop a microRNA-based diagnostic for the early detection of Alzheimer's disease.

Under the deal, Rosetta will provide the pharma with miRNA profiling services and expertise. Additional terms of the arrangement were not disclosed.

Filed under

Gene Silencing/Gene Editing
Neurological & Psychological Disorders
Alzheimer's disease
RNAi
miRNA
Rosetta Genomics
Breaking News
The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.